No profile data available.
Cognition Therapeutics, Inc. (CGTX) is a healthcare company in the brain and nerve treatment drugs industry, based in Purchase, United States, with about 14 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$23.49 million. Its market capitalization was $83.39 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
Cognition Therapeutics reported $0 in revenue for fiscal year 2025.
$83.39 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Coya Therapeutics, Inc. (COYA), Neumora Therapeutics, Inc. (NMRA), ProMIS Neurosciences, Inc. (PMN), MediciNova, Inc. (MNOV).